GSK announces US regulatory submission for fluticasone furoate monotherapy for asthma
Issued: Wednesday 23 October 2013, London UK
GlaxoSmithKline plc (LSE:GSK) today announced the submission of a New Drug Application (NDA) in the US for the once daily inhaled corticosteroid (ICS) treatment, fluticasone furoate (FF), administered using the ELLIPTA™ dry powder inhaler.
The NDA has been submitted to the US Food and Drug Administration (FDA) for FF monotherapy (100mcg and 200mcg doses) as a once-daily inhaled dry powder maintenance treatment of asthma as prophylactic therapy in patients aged 12 years and older.
Regulatory filings for FF monotherapy are planned in other countries from 2014 onwards. FF administered using the ELLIPTA™ dry powder inhaler is an investigational medicine and is not currently approved anywhere in the world.
ELLIPTA™ is a trademark of the GlaxoSmithKline group of companies.
GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.